Dr. William KC Park Profile

Dr. William KC Park

Assistant Professor/Research Associate at Brown Univ

SPIE Involvement:

Author

Publications (2)

Proceedings Article | 22 February 2017 Paper

A novel thermal accelerant for augmentation of microwave energy during image-guided tumor ablation

William K. Park, Aaron W. Maxwell, Victoria Frank, Michael Primmer, Jarod Paul, Cynthia Susai, Scott Collins, Tiffany Borjeson, Greyson Baird, Kara Lombardo, Damian Dupuy

Proceedings Volume 10066, 1006602 (2017) https://doi.org/10.1117/12.2249772

KEYWORDS: Microwave radiation, Computed tomography, Medium wave, In vitro testing, Antennas, Tumors, Polymers, Temperature metrology, Dielectrics, Molecules

Read Abstract +

Proceedings Article | 22 February 2017 Paper

A ferritin-containing nanoconjugate as MRI image-guidance to target Necl-5, a tumor-surface antigen: a potential thermal accelerant for microwave ablation

William K. C. Park, David Mills, Sierin Lim, Barindra Sana, Victoria Frank, Brendan Kenyon, Michael Primmer, Jarod Paul, Greyson Baird, Edward Walsh, Damian Dupuy

Proceedings Volume 10066, 100660H (2017) https://doi.org/10.1117/12.2250041

KEYWORDS: Magnetic resonance imaging, Veins, Cancer, Oncology, Tumors, Tissues, Iron, Nanoparticles, Liver, Magnesium

Read Abstract +

Purpose: A ferritin-containing nanoparticle conjugated with a target-specific antibody was investigated as a MRI contrast agent for tumor detection. A genetically modified ferritin to markedly improve Fe (III) payload (up to 7,000 Fe ions), was chemically tethered to a monoclonal antibody against rat Nectin-like molecule 5 (Necl-5). Necl-5 is a cell surface glycoprotein that is highly expressed on the cell surface of many common epithelial cancers, including prostate cancer. It was previously demonstrated that this novel nanoconjugate agent exhibited effective in vitro targeting of Necl- 5 expressing tumor cells and exhibited strong MRI contrast characteristics via shortening of T₂. Here, we demonstrate that the nanoconjugate-Necl-5 interaction can be exploited to target and detect tumor in vivo by MRI. Procedure: Using an in vivo tumor model (i.e., tumor size 0.5^-1 cm, immunodeficient beige/nude/xid mouse, xenograft injection with transformed rat prostate cells), efficacy of the conjugate targeting the tumor was examined. We used two injection strategies, a direct and a tail vein injection (0.8 mg, 300 μL per subject). Pre-injection baseline and postinjection scans were performed with the following spin-echo sequence parameters: Field of view = 90x53mm, reconstruction matrix size = 192x114, slice thickness = 1mm (10 slices), repetition time (TR) = 2070 ms, echo times (TE) = 11-198 ms in 11ms steps (18 echoes), number of averages = 2, acquisition time per scan = 7min 56s. Results: All T₂ data obtained were converted to R₂ for demonstration purposes (R₂ = 1/T₂). The tail vein injected conjugate significantly increased R₂ response (22.9 ± 5.2 s^-1) as compared to control (13.5 ±1.7 s^-1) at 4 h. The weaker R₂ increase was noted (15.2 ± 2.0 s^-1) at 24 h. No notable changes in R₂ were observed in surrounding tissues regardless the stages of the measurement. We also measured the initial conjugate kinetics for both injection methods with respect to the ability of targeting the tumor. Direct injection of the nanoconjugate in to the center of the tumor showed a stronger and more rapid increase in R2 than the tail vein injection. Conclusion: The nanoconjugate interacts strongly and selectively in situ with Necl-5 overexpressing tumor cells. Direct injection of the nanoconjugate into the body of the tumor caused a more significant in situ R₂ increase in MRI than the tail vein injection. Varying degrees of R₂ increase within the tumor mass is likely to represent different distribution patterns of the conjugate, reflective of tumor heterogeneity.

View contact details

UPDATE YOUR PROFILE

Is this your profile? Update it now.

Sign into your SPIE.org account

Don’t have a profile and want one?

Create an account on SPIE.org

Keywords/Phrases

Search In:

Publication Years